{"id":"NCT04779242","sponsor":"Paratek Pharmaceuticals Inc","briefTitle":"Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia","officialTitle":"A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-25","primaryCompletion":"2024-03-27","completion":"2024-03-27","firstPosted":"2021-03-03","resultsPosted":"2025-04-09","lastUpdate":"2025-04-09"},"enrollment":670,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Community-acquired Pneumonia","Bacterial Pneumonia"],"interventions":[{"type":"DRUG","name":"Omadacycline","otherNames":["NUZYRA"]},{"type":"DRUG","name":"Moxifloxacin","otherNames":["Avelox"]}],"arms":[{"label":"Omadacycline","type":"EXPERIMENTAL"},{"label":"Moxifloxacin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.","primaryOutcome":{"measure":"Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit","timeFrame":"72 to 120 hours after the first dose of test article","effectByArm":[{"arm":"Omadacycline","deltaMin":89.6,"sd":null},{"arm":"Moxifloxacin","deltaMin":87.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":55,"countries":["Bulgaria","Croatia","Georgia","Hungary","Poland","Russia","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":336},"commonTop":["Headache","COVID-19","Diarrhoea","Insomnia","Aspartate aminotransferase increased"]}}